Alternative funding programs in pharma were once viewed mainly as a payer issue, but they are becoming a much broader patient-access challenge. These programs can exclude selected specialty drugs from employer-sponsored coverage and then direct patients toward other sources of funding, including manufacturer patient assistance programs (PAPs). In effect, a benefit-design decision can shift financial responsibility while placing manufacturers, patients, providers, and assistance programs in a new and often complicated access pathway. For pharma leaders, the central question is no longer simply who has coverage. It is who ultimately pays when that coverage does not include the prescribed therapy.
Table of Contents
- How alternative funding programs change specialty drug access
- Why patient assistance programs are under pressure
- What AFPs mean for pharma brand and market access teams
- How manufacturers can adapt their patient-support strategy
- Conclusion
- Frequently asked questions
How Alternative Funding Programs Change Specialty Drug Access
Alternative funding programs, or AFPs, are generally offered by third-party vendors working with self-funded employer health plans. Instead of covering certain high-cost specialty medications through the normal pharmacy or medical benefit, a plan may exclude those therapies. The AFP vendor then attempts to find another way for the patient to obtain the prescribed drug.
Frequently, that alternative route includes a manufacturer PAP or another assistance source. In some models, other sourcing pathways may also be explored. As a result, the traditional relationship between insurance coverage, patient affordability, and manufacturer support becomes less clear.
A peer-reviewed Journal of Managed Care & Specialty Pharmacy study illustrates the potential patient impact. Among 227 surveyed patients with AFP experience, 61% said they first learned about the program when trying to obtain their medication. Moreover, patients reported waiting an average of about 68 days to receive medication, while 24% said the wait worsened their condition.
These findings matter because specialty therapy often depends on a predictable access journey. When a prescription suddenly encounters an exclusion rather than a conventional formulary decision, patients and providers may not immediately understand what comes next. Consequently, support hubs, field reimbursement teams, and specialty pharmacies may face questions that conventional benefit-verification workflows were not designed to answer.
Why Patient Assistance Programs Face New AFP Pressure
Manufacturer PAPs traditionally serve as an important safety net for eligible uninsured or underinsured patients. Eligibility requirements vary, but programs often consider income, insurance status, and other financial circumstances. Alternative funding programs can complicate that mission when commercially insured patients are directed toward assistance after their employer plan excludes a specialty drug.
That creates an important distinction for manufacturers. A patient may technically have commercial health insurance while lacking coverage for the specific specialty therapy being prescribed. Therefore, determining whether that person fits the intended purpose and eligibility rules of a PAP can become more complicated.
The growing challenge of alternative funding programs for pharma is partly about protecting the sustainability and intended purpose of patient assistance. AFP arrangements may shift costs that otherwise could have been paid by an employer-sponsored plan toward manufacturer-funded programs. Industry analysis has consequently argued that manufacturers need to examine PAP strategy rather than treat AFP activity as a narrow operational issue.
At the same time, patients can get caught between these competing financial interests. A person may hear that a medication is “not covered” despite having employer-sponsored insurance. Next, that patient may be asked to provide personal and financial information to a third-party vendor while waiting to learn whether another funding route is available.
The PAN Foundation’s guidance on alternative funding programs explains how coverage exclusions can redirect patients toward outside assistance pathways. For pharma companies, this means affordability programs increasingly operate within a broader ecosystem of employer benefit design, vendor intervention, and specialty-drug cost management.
What AFPs Mean for Pharma Brand and Market Access Teams
For brand leaders, the AFP issue can initially look like something that belongs entirely to market access or patient services. However, the patient rarely experiences those corporate divisions. Patients simply know that they were prescribed a medicine and encountered a barrier when trying to obtain it.
Therefore, pharma strategies for responding to alternative funding programs should connect brand planning with market access, patient services, reimbursement support, and specialty pharmacy insights. A brand team that understands formulary position but lacks visibility into AFP exclusions may have an incomplete picture of real-world access.
Patient communications also deserve attention. Materials that broadly tell commercially insured patients to check their benefits may no longer provide enough guidance when specialty medications can be carved out. Instead, patient-support resources may need to explain what to do after an unexpected coverage exclusion and how to contact legitimate manufacturer support services.
Similarly, healthcare professional communications should account for these new access pathways. Prescribers and office staff may encounter denials that differ from familiar prior authorization or step-therapy processes. Clear education can help them recognize when an AFP may be involved and direct patients toward appropriate support.
For pharmaceutical marketers, this is also a reminder that the access experience influences the brand experience. Digital engagement cannot stop at awareness or treatment consideration when patients encounter complicated affordability barriers after receiving a prescription. Stronger coordination among marketing, access, and patient-support functions can help brands provide useful information at the moment patients need it.
How Pharma Can Rethink Patient Assistance and Access Strategy
The first priority is visibility. Manufacturers need ways to identify patterns that suggest AFP involvement, including unusual coverage exclusions, changes in PAP application volume, repeated vendor interactions, and shifts in specialty pharmacy referrals. Better intelligence can help teams understand where the patient journey is changing.
Next, companies should review PAP eligibility language and operational processes. Rules should support the program’s intended population while addressing situations in which commercial coverage has been structured to exclude particular specialty drugs. However, any changes require careful legal, compliance, and patient-access review.
Manufacturers should also map the entire access journey from prescription to therapy initiation. That exercise can reveal where AFP involvement adds paperwork, confusion, or delays. More importantly, it can show where patient-support teams can provide clearer guidance without making assumptions about eligibility.
Communication is another critical piece. Pharma companies should explain assistance requirements clearly to patients and providers while avoiding promises that every patient will qualify. When someone needs individualized medical guidance, they should speak with their healthcare professional or use a trusted healthcare resource such as Healthcare.pro.
Finally, pharma organizations need cross-functional ownership. AFPs touch market access, patient services, trade and distribution, legal, compliance, analytics, communications, and brand strategy. No single department sees the entire problem. Consequently, a coordinated response can help protect patients while preserving the purpose and sustainability of assistance programs.
Conclusion
Alternative funding programs are changing who pays for specialty medicines and how patients reach therapy. What appears to be an employer cost-management strategy can quickly become a manufacturer patient-assistance issue, a provider workflow problem, and, most importantly, a patient access challenge.
For pharma, responding effectively means looking beyond individual PAP applications. Companies need better visibility into AFP activity, clearer assistance rules, stronger patient and provider communications, and closer coordination between brand, market access, and patient-support teams.
As alternative funding programs play a larger role in specialty drug access, pharma leaders will need to do more than simply close potential loopholes. The broader goal should be to build access systems that recognize changing benefit designs while helping appropriate patients navigate the resulting complexity.
Frequently Asked Questions
What are alternative funding programs in pharma?
Alternative funding programs are third-party arrangements often used with self-funded employer health plans to reduce spending on specialty medications. Certain drugs may be excluded from coverage, after which a vendor seeks another source that could help the patient obtain therapy.
How do AFPs affect manufacturer patient assistance programs?
Some AFP vendors may direct commercially insured patients toward manufacturer PAPs after a specialty medication is excluded from their employer plan. This can raise questions about eligibility, program resources, and the intended purpose of manufacturer assistance.
Can alternative funding programs delay specialty drug access?
Yes. Delays can occur while patients navigate coverage exclusions and alternative assistance applications. A published survey of patients with AFP experience reported an average wait of about 68 days to receive medication.
Why should pharma marketing teams care about AFPs?
Access problems affect both the patient experience and the brand experience. Marketing teams therefore benefit from coordinating with market access and patient services so communications reflect the barriers patients may encounter after a prescription is written.
What should pharmaceutical companies do about AFP growth?
Companies can monitor AFP activity, review PAP eligibility and workflows, map changing patient journeys, improve provider and patient education, and coordinate decisions across market access, patient services, compliance, and brand teams.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
